Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Thursday, November 4, 2010, to discuss the company’s financial results for the second quarter of fiscal 2011. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes’ website at www.alkermes.com or may be accessed by dialing 1-888-517-2470 for domestic callers and 1-630- 827-6818 for international callers. The conference call ID number is 7262488.

A replay of the conference call will be available from 7:30 p.m. ET on Thursday, November 4, 2010, through 5:00 p.m. ET on Thursday, November 11, 2010, and may be accessed by visiting Alkermes’ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 7262488.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol and opioid dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.



CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Chief Operating Officer Dan Paterson will lead the company while it looks for a permanent successor with commercial chops.

The job losses are part of Sanofi's pivot away from cardiovascular diseases and toward immuno-oncology drugs and gene therapies.

Parexel is looking to bolster its clinical trial work and compliance by signing a new deal with CluePoints.